DAX ®13.576,68+1,41%TecDAX ®3.225,97+1,75%Dow Jones28.989,73-0,58%NASDAQ 1009.141,47-0,82%
finanztreff.de

BUSINESS WIRE: European Launch of ResistancePlus MG FleXible for the GeneXpert System

| Quelle: Business_Wire | Lesedauer etwa 3 min. | Text vorlesen Stop Pause Fortsetzen

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.

SpeeDx to bring first sample-to-answer Mycoplasma genitalium and macrolide resistance test to Europe

SYDNEY (BUSINESS WIRE) 16.12.2019

SpeeDx Pty, Ltd. today announced the European launch of ResistancePlus® MG FleXible, the first sample-to-answer test for detecting the sexually transmitted infection (STI) Mycoplasma genitalium (Mgen) and markers associated with azithromycin resistance. Cepheid is the exclusive distribution partner of this test, available through Cepheid’s FleXible Cartridge programme for the GeneXpert System.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191215005039/en/

Management guidelines around the world, including those recently updated in France1 and the U.K.2, reference testing the macrolide resistance status of Mgen infections in order to more effectively treat patients. Mgen can cause symptoms such as urethritis, cervicitis, endometritis and pelvic inflammatory disease, and has been linked to reproductive health complications including pre-term birth and infertility.2,3 Due to the challenges of rising antimicrobial resistance and a lack of clear data that asymptomatic infection leads to protracted health complications, Mgen testing guidelines are unanimous in their recommendation to only test symptomatic individuals.

“This is an important test expansion for the thousands of GeneXpert Systems on the market,” said Colin Denver, SpeeDx CEO. “ResistancePlus MG FleXible enables Resistance Guided Therapy, supporting more clinicians to adhere to testing guidelines and maximising effective care for their patients infected with Mgen.”

Both SpeeDx and Cepheid will be showcasing ResistancePlus MG at RICAI (Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse) December 15th and 16th in Paris. Visit SpeeDx booth #41bis and Cepheid booth #18 to learn more.

About SpeeDx

SpeeDx has developed a molecular diagnostics test portfolio, principally for infectious diseases, that provides both identification as well as therapeutic guidance capabilities. The company is based in Australia with offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. The SpeeDx ResistancePlus® MG open-platform assay is CE marked for sale in Europe, TGA approved for sale in Australia and clinical trials are being finalised for submission to the U.S. FDA. Products in the SpeeDx portfolio focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease.

For more information on SpeeDx please see: https://plexpcr.com

  1. https://www.sfdermato.org/site/groupe-infectiologie-dermatologique-et-infections-sexuellement-transmissibles.html
  2. https://www.bashhguidelines.org/media/1146/ngu-update-05_2017-final.pdf
  3. http://www.sti.guidelines.org.au/sexually-transmissible-infections/mycoplasma-genitalium

 

SpeeDx:
Europe, Australia, New Zealand:
Madeline O’Donoghue
+61 2 9209 4170
madelineo@speedx.com.au

Cepheid:
Darwa Peterson
darwa@cepheid.com
Tel. + 1.408.400.4324

Werbung

Das könnte Sie auch interessieren

Weitere Nachrichten

Quelle: Business_Wire
25.01. BUSINESS WIRE: HCL Technologies ehrt globale Goodwill Champions beim Weltwirtschaftsforum 2020 in Davos
24.01. BUSINESS WIRE: Sierra Metals meldet überragende Produktionsergebnisse für 2019 und veröffentlicht Prognose für 2020
24.01. BUSINESS WIRE: HighRes Biosolutions e Novo Nordisk si alleano per trasformare la scoperta di farmaci nel laboratorio automatizzato del futuro
24.01. BUSINESS WIRE: HighRes Biosolutions und Novo Nordisk arbeiten gemeinsam an Transformation der Arzneimittelentwicklung im automatisierten Labor der Zukunft
24.01. BUSINESS WIRE: Conquest investe in 5 parchi eolici terrestri greenfield per un totale di 43MW generati nella regione delle Fiandre
24.01. BUSINESS WIRE: HCL Technologies celebra personaggi da tutto il mondo che si sono distinti per il loro impegno civile e sociale al Forum economico mondiale 2020 di Davos
24.01. BUSINESS WIRE: Conquest investiert in 5 Greenfield-Onshore-Windparks mit einer Gesamtleistung von 43 MW in der Region Flandern
24.01. BUSINESS WIRE: Deutsche Gewächshausregion Emsland entscheidet sich für Fluence by Osram
24.01. BUSINESS WIRE: Fluence amplia la sua presenza nell'area EMEA grazie alla collaborazione con i produttori di Papenburg, in Germania
24.01. BUSINESS WIRE: Ipsen’s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteria IPSEN S.A. PORT. EO 1 63,00 -23,22%
Rubrik: Finanzmarkt
26.01. dpa-AFX-Überblick: UNTERNEHMEN - Die wichtigsten Meldungen vom Wochenende
26.01. ROUNDUP: Trumps Verteidiger halten Impeachment-Vorwürfe für ungültig
26.01. OTS: Messe Berlin GmbH / A b s c h l u s s b e r i c h t Grüne Woche 2020: ...
26.01. VIRUS/ROUNDUP: Zahl der Virus-Toten steigt - China verschärft Maßnahmen deutlich
26.01. Trump geht Impeachment-Ankläger scharf an - Der sieht das als Drohung
26.01. 'HB': Investor Petrus nimmt Aareal Bank ins Visier COMDIRECT 13,80 +1,47%
26.01. ROUNDUP/Umfrage: Technologischer Wandel beunruhigt die Deutschen
26.01. Heil verteidigt Grundrenten-Pläne - Brinkhaus fordert Korrekturen
26.01. VIRUS/Medien: Behandlungserfolge im Kampf gegen Lungenkrankheit in China
26.01. Deutsche Industrie will Huawei vom Aufbau des 5G-Netzes ausschließen

News-Suche

Suchbegriff:
Werbung

Werbung
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook oder Twitter
Wenn Sie auf die Teilen-Buttons klicken und sich bei den Betreibern einloggen, werden Daten an den jeweiligen Betreiber übermittelt. Bitte beachten Sie die Datenschutzerklärung.
Aktuelle Umfrageschliessen
Wie, glauben Sie, wird der DAX am Ende dieser Woche - KW 5 - stehen?
Jetzt abstimmen!
Alle Umfragen ansehen